Loading the session
Loading the session
Loading instrument
$165.50
+0.39%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:27 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $166.05 was 13.0% above its 50-day average ($146.98) and 12.4% above its 200-day average ($147.76). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed below the 200-day on 27 Oct 2026, 6 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
1 month: +14.1% (SPY −1.6%, XLV +13.5%). 3 months: +2.8% (SPY −0.4%, XLV +15.5%). 1 year: +16.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NBIX, SPY and XLV · as of 4 Nov 2026
The 14-session relative strength index closed at 77.2 on 4 Nov 2026, its 2nd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Closed at $166.05 on 4 Nov 2026: 10.8% below the 52-week high of $186.12 (30 Jul 2026) and 36.0% above the low of $122.14 (12 Feb 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 2.3M shares was 1.6× the average of the 30 sessions before it (1.4M), as the price rose 0.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
November 3, 2026
+13.42%February 7, 2025
−18.53%August 28, 2024
−18.87%